European indapamide market is estimated to grow significantly at a CAGR of around 3.2% during the forecast period. Europe has a huge economic burden of heart-related diseases such as CVD, CHD, stroke, and other heart diseases. Europe region including UK, Spain, Germany, France, Italy, Sweden, and other EU countries have a huge pool of CVD patients that creates scope for the growth of the indapamide market. The European Stroke Organization (ESO) and Stroke Alliance for Europe (SAFE) published European Stroke Action Plan (ESAP) in May 2018. The aim of the plan is to set a roadmap and goals for the treatment of stroke in Europe by 2030.Indapamide is used as a preventive treatment of stroke in combination with perindopril, therefore, the growing stroke cases in the region further contribute to the growth of the market during the forecast period. 

The European indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

The companies which are contributing to the growth of the European indapamide market include Merck KGaA, Sanofi S.A., Mylan N.V., Laboratori Baldacci S.p.A., Sandoz International GmbH, Bioindustria L.I.M. S.p.A. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the European indapamide market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for indapamide market players, potential entrants and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. European Indapamide Market Research and Analysis by Product
2. European Indapamide Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the European indapamide market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European indapamide market.
• Insights about market determinants which are stimulating the European indapamide market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.